Medulloblastoma (MB) is the most common malignant brain tumor in children. It is known that overexpression and/or amplification of the MYC oncogene is associated with poor clinical outcome, but the molecular mechanisms and the MYC downstream effectors in MB remain still elusive. Besides contributing to elucidate how progression of MB takes place, most importantly, the identification of novel MYC-target genes will suggest novel candidates for targeted therapy in MB. A group of 209 MYC-responsive genes was obtained from a complementary DNA microarray analysis of a MB-derived cell line, following MYC overexpression and silencing. Among the MYC-responsive genes, we identified the members of the bone morphogenetic protein (BMP) signaling pathway, which have a crucial role during the development of the cerebellum. In particular, the gene BMP7 was identified as a direct target of MYC. A positive correlation between MYC and BMP7 expression was documented by analyzing two distinct sets of primary MB samples. Functional studies in vitro using a small-molecule inhibitor of the BMP/SMAD signaling pathway reproduced the effect of the small interfering RNA-mediated silencing of BMP7. Both approaches led to a block of proliferation in a panel of MB cells and to inhibition of SMAD phosphorylation. Altogether, our findings indicate that high MYC levels drive BMP7 overexpression, promoting cell survival in MB cells. This observation suggests the potential relevance of targeting the BMP/SMAD pathway as a novel therapeutic approach for the treatment of childhood MB.
Medulloblastoma (MB) is the most common malignant brain tumor in children. It is known that overexpression and/or amplification of the MYC oncogene is associated with poor clinical outcome, but the molecular mechanisms and the MYC downstream effectors in MB remain still elusive. Besides contributing to elucidate how progression of MB takes place, most importantly, the identification of novel MYC-target genes will suggest novel candidates for targeted therapy in MB. A group of 209 MYC-responsive genes was obtained from a complementary DNA microarray analysis of a MB-derived cell line, following MYC overexpression and silencing. Among the MYC-responsive genes, we identified the members of the bone morphogenetic protein (BMP) signaling pathway, which have a crucial role during the development of the cerebellum. In particular, the gene BMP7 was identified as a direct target of MYC. A positive correlation between MYC and BMP7 expression was documented by analyzing two distinct sets of primary MB samples. Functional studies in vitro using a small-molecule inhibitor of the BMP/SMAD signaling pathway reproduced the effect of the small interfering RNA-mediated silencing of BMP7. Both approaches led to a block of proliferation in a panel of MB cells and to inhibition of SMAD phosphorylation. Altogether, our findings indicate that high MYC levels drive BMP7 overexpression, promoting cell survival in MB cells. This observation suggests the potential relevance ofIntroduction Medulloblastoma (MB) represents >20% of all pediatric tumors of the central nervous system (Gurney and Kadan-Lottick, 2001) , and is characterized by aggressive clinical behavior and high risk of leptomeningeal dissemination (Engelhard and Corsten, 2005) . Multimodal therapy (surgery, radiotherapy and chemotherapy) has improved the overall survival rate. However, about 30% of patients are still incurable, and survivors often suffer from severe tumor-and therapy-related cognitive and neurological dysfunctions (Mulhern et al., 2005) . MB can be subdivided into different histological variants (Eberhart et al., 2002; Lamont et al., 2004) ; the large-cell/anaplastic MB (20-25% of patients) represents the most aggressive subtype, and is associated with a high degree of genomic instability and deregulated expression of the oncogene MYC (Stearns et al., 2006; Gilbertson and Ellison, 2008) .
MYC represents a family of pleiotropic transcription factors that activate/repress a large group of target genes (Grandori et al., 2000; Adhikary and Eilers, 2005) that are, in turn, the effectors of MYC-dependent biological responses, ranging from cell growth, proliferation and migration to programmed cell death and differentiation. MYC is primarily expressed during development and is mainly repressed in adult tissues, in which aberrant expression (upregulation) can drive neoplastic transformation (Littlewood and Evan, 1990) . In MB, MYC upregulation can originate from genomic amplification (4-10% of MB patients; Neben et al., 2004) or mRNA overexpression (30-65% of patients; Herms et al., 2000; Aldosari et al., 2002) , and it can occur as a downstream effect of deregulated signaling pathways (Guessous et al., 2008) that are involved in the development of granule neuron precursor cells (GNPs) of the cerebellum (Gilbertson and Ellison, 2008) .
Different approaches have been evaluated to target MYC in various malignancies, including MB (Vita and Henriksson, 2006; Grotzer et al., 2009) . However, direct pharmacological targeting of transcription factors has proven difficult, thus warranting the effort of investigating in more detail genes that are downstream of MYC as novel therapeutic targets. Furthermore, a selective targeting of downstream effectors would aim at preserving the anti-proliferation (for example pro-apoptotic) functions of MYC.
In this study, we combined gene expression data from MB-derived cell lines, which had been engineered to either overexpress or silence MYC. Among the MYCresponsive genes, we searched for candidate drivers of MYC-dependent tumorigenesis in MB. The results suggested the possible relevance of bone morphogenetic proteins (BMPs), which are cytokines of the family of the transforming growth factor-b (Blanco Calvo et al., 2009) . BMPs can be activated, both in a paracrine and autocrine way, to promote recruitment of cell surface serine/threonine kinase receptors, thus triggering activation of SMAD transcription factors (Miyazono et al., 2005 (Miyazono et al., , 2010 .
Many studies report on alterations of the BMP pathway in several tumor systems, including breast, prostate, lung, and colon cancers, as well as glioblastoma, osteosarcoma and MB (Arihiro and Inai, 2001; Langenfeld et al., 2003; Miyazaki et al., 2004; Raida et al., 2005; Piccirillo and Vescovi, 2006; Ye et al., 2007; Buijs et al., 2007a; Dai et al., 2008) . Similar to other transforming growth factor-b members (Derynck et al., 2001) , BMPs may have a dual role in cancer, both promoting and repressing tumorigenesis in several models (Buijs et al., 2007a, b; Ye et al., 2009; Thawani et al., 2010) . BMP7, for instance, was shown to promote migration and invasion of prostate cancer cells (Feeley et al., 2005) , but also to inhibit prostate tumor cell growth in vivo (Buijs et al., 2007b) . Miyazaki et al. (2004) showed a dose-dependent effect of BMP7, which inhibited proliferation of androgen-insensitive prostate cells at high concentrations, whereas low doses had a pro-proliferative effect. In breast cancer, the expression level of BMP7 was found inversely correlated to tumorigenicity and invasiveness in vitro (Buijs et al., 2007a) , but it was also found to cause abnormal proliferation in p53-deficient breast cancer cells when knocked down (Yan and Chen, 2007) . Although apparently contradictory, these data reflect the complexity of the BMP/SMAD signaling pathway (Ye et al., 2009) , leading to diverse heterogeneous cellular responses, which can be tissue-and cell type-specific and result from the cross-talk with the microenvironment. This latter heavily influences the temporal and spatial expression of BMPs (Sieber et al., 2009) , implying also that co-expression of antagonists (Walsh et al., 2010; Yanagita, 2005) or modulators (Balemans and Van Hul, 2002; Yanagita, 2009) , as well as the activation status of other pathways (Miyazono et al., 2005; Guo and Wang, 2009) , all contribute significantly to the diverse responses observed.
Finally, because of the relevance of BMPs during cerebellum development (by regulating proliferation, cell cycle exit, migration and differentiation of GNPs; Gilbertson and Ellison, 2008) , it is not surprising that BMPs are likely to have a role in tumorigenesis and at least in a subset of MB tumors (Thompson et al., 2006; Grimmer and Weiss, 2008; Behesti and Marino, 2009; Sutter et al., 2010) . In this respect, our experimental results are consistent with this biological hypothesis and provide an important contribution by linking, for the first time, a BMP family member to the oncogene MYC, in the context of MYC-dependent prosurvival mechanisms in MB.
Results

Identification of MYC-responsive genes in a model of MB
To identify MYC-driven tumorigenic functions in MB, DAOY and DAOY-derived cells were genetically manipulated to either enhance or silence MYC expression (Stearns et al., 2006) , and their expression profiles were analyzed by cDNA microarray. In one set of experiments, we evaluated the transcriptional changes induced by MYC upregulation in DAOY cells by comparing the profiles of two MYC-overexpressing clones (DAOY M2.1 and M14) with those of wild-type DAOY and empty-vector-transfected DAOY V11 cells. The two clones shared 98% similarity in differentially expressed genes, they were substantially identical in terms of transcriptional changes associated with MYC expression on the genetic background of DAOY cells. The lists of genes associated with MYC overexpression in DAOY M2.1 and M14 cells were intersected to select only common genes and corrected for the contribution of the empty vector. This analysis enabled us to define a list of genes associated with MYC overexpression. In addition, we analyzed the transcriptome of DAOY M2.1 cells transfected with MYC-specific small interfering RNA (siRNA) normalized to control/non-targeting siRNA and found a group of genes associated with MYC knockdown. In this latter set of experiments, the expression analysis was carried out at 48 h post transfection. This time point was chosen because it showed the most efficient downregulation of MYC and of its known direct target telomerase reverse transcriptase (TERT) (Supplementary Figure S1A) . Figure 1 shows the variation of MYC in all cell lines in the study, at both the mRNA ( Figure 1a ) and protein (Figure 1b ) levels.
To select only those entities up/downregulated in a consistent manner in both sets of experiments, we intersected the two lists of genes. We obtained a group of 209 genes that were responsive to MYC gene modulation with absolute fold change X2.0 and P-value o0.01 ( Figure 1c) . Of the 209 genes, 105 were Table 1 ). This group of genes was analyzed by using different bioinformatics tools, such as GeneGO MetaCore, that allowed us to draw functional networks between genes based on the literature.
Our experimental data included several known direct targets of MYC, such as CCND2 (Adhikary and Eilers, 2005) and TERT (Wu et al., 1999) , which overlapped with the MYC-target gene database (www.myccancergene.org/site/mycTargetDB.asp). In fact, overexpression of MYC increased the CCND2 level by 3.1-and 2.3-fold in DAOY M2.1 and M14 cells, respectively, whereas MYC silencing repressed the same gene by 8.4-fold. In contrast, a gene that is known to be negatively regulated by MYC, inhibin-b A (INHBA), was significantly downregulated in DAOY M2.1 and in DAOY M14 cells (3.8-and 3.7-fold change, respectively) and upregulated on MYC silencing (3.9-fold change). The cDNA microarray data were validated by quantifying the mRNA expression level of a group of representative MYC-target genes. The expression changes of TERT and CCND2 following both upregulation (Supplementary Figure S1B ) and silencing of MYC (Supplementary Figure S1C) are reported. As a negative control, the expression of cyclin A2 (CCNA2), which is not a target of MYC, was analyzed (Supplementary Figure S1A, 
B).
Effect of MYC modulation on components of the BMP pathway Growing evidence suggests the functional relevance of BMPs in the onset of a subset of MB tumors, which is currently attributed to abnormal development of GNP cells of the external granular layer of the cerebellum (Marino, 2005; Crawford et al., 2007; Gilbertson and Ellison, 2008; Sutter et al., 2010) . Interestingly, several members of the BMP pathway were differentially expressed following overexpression or silencing of MYC (Table 1) , suggesting a regulatory effect of MYC on this pathway in MB.
In particular, a general increase in the mRNA expression levels of some BMP ligands (BMP2, 6 and 7) in DAOY M2.1 cells hinted at MYC-dependent activation. Moreover, subtypes of BMP receptors (BMPRs) type I-II were also represented, although only a few of them could be validated in our cellular models. Similar to the majority of BMPs, the mRNA level of glypican-3 (GPC3), a soluble inhibitor of BMPs (Grisaru et al., 2001; Filmus et al., 2008) , increased with MYC upregulation, and it may be responsible for a negative-feedback loop on the pathway. Finally, our microarray data did not show significant alteration of members of the SMAD family of transcription factors or of the SMAD-target genes inhibitors of differentiation (ID; Miyazono, 1999) . This observation would imply the involvement of alternative downstream effectors, not fully characterized yet.
BMP7 as downstream target of MYC in MB
The correlation analysis performed by using GeneGO set a subgroup of the selected 209 MYC-responsive genes in direct and functional links with MYC, according to published data (Supplementary Figure  S2) . In particular, several networks revealed a direct correlation between MYC and BMP7, which we studied in more detail, trying to elucidate the MYC-dependent regulation of BMP7 and the relevance of the BMP pathway in our model of MB. From the gene expression profiling data, BMP7 was upregulated in MYC-overexpressing DAOY M2.1 and M14 cells (2.1-and 8.7-fold change, respectively), whereas BMP7 was repressed in cells silenced for MYC (2.6-fold change; Table 1 ). Another BMP member, BMP6, was found strongly upregulated on MYC overexpression (9.4-fold change). However, on MYC silencing, the transcriptional level of BMP6 did not consistently correlate with MYC levels (1.7-fold-change; Table 1 ).
To demonstrate that the MYC transcription factor regulates transcription of BMP7, the ability of MYC to bind the promoter of BMP7 was evaluated by chromatin immunoprecipitation (ChIP), performed in different MB cell lines. Genomic DNA was extracted and precipitated with a MYC-specific antibody to enrich for MYC-binding promoter sequences, which were hybridized to a promoter oligo array (Ma et al., 2010) . We observed an enrichment of DNA fragments surrounding the transcriptional start site of BMP7, including regions that contain canonical binding sites for MYC (Figure 2 ), demonstrating that MYC can regulate the expression of BMP7 by binding the BMP7 promoter.
BMP7 is expressed in MB tumor samples and correlates with MYC expression A total of 66 samples of MB available as a tissue microarray (TMA) were probed for BMP7 immunoreactivity. Cytoplasmic expression of BMP7 was quantified as positive in 10-50% cells in 17 tumors (26% MBs), as 51-90% cells in 16 tumors (24% MBs) and as 490% cells in 14 tumors (21% MBs), whereas 19 tumors (29%) expressed no BMP7 (Figure 3a and b) . Notably, BMP7 could not be detected in any of the 16 normal cerebellum cores (Figure 3c ). Normal human renal tubule cells were used as a positive control, as they express high levels BMP7 in the cytosol (Figure 3d) .
To find a possible correlation between BMP7 and MYC in primary MBs, the mRNA expression levels of both genes were determined in 38 MB samples from the TMA. The results clearly indicated a positive correlation between BMP7 and MYC (Pearson's correlation value ¼ 0.42; P-value ¼ 0.0095; Figure 3e ). The observation that BMP7 and MYC positively correlate in primary tumors was confirmed by the unsupervised analysis of a different set of gene expression data, obtained from 46 MBs previously published by Thompson et al. (2006; Supplementary Figure S3) . Although this analysis showed the correlation of BMP7 with MYC expression in primary tumors, no significant correlation was found between MYC and other BMP members (from Table 1 ).
MYC-dependent expression of BMP7 and SMAD1/5/8 activation in MB cells
The MYC-dependent expression of BMP7 was validated in different cell lines (Figure 4) . MYC overexpression significantly increases the mRNA level of BMP7 (Figure 4a ). On the other hand, BMP7 was downregulated in DAOY M2.1 cells transfected with MYC siRNA (Figure 4b ), similarly to TERT that is a known MYC direct target gene (see also Supplementary Figure  S1A) . Although BMP6 mRNA increased on MYC overexpression, no effect was observed by silencing the oncogene. We could not find a significant correlation between the expression of BMP6, MYC and TERT (Supplementary Figure S1A) .
To discriminate between the intracellular and the secreted (active) form of BMP7, both total cell lysates and supernatants were analyzed for BMP7 expression, by immunoblotting (Figure 4c ) and enzyme-linked immunosorbent assay (ELISA; Figure 4d ), respectively. The results confirmed that the MYC-dependent expression of BMP7 induced also an increase of the BMP7 protein, both in the precursor and the mature secreted form. In fact, BMP7 was detectable in the supernatant only in MYC-overexpressing cells, whereas it was undetectable (both in total cell lysates and supernatant) in cells bearing only one MYC copy (Figure 4c caused depletion of BMP7 in cell lysates ( Figure 4C , right panel) as well as in the medium (Figure 4e) .
Next, we investigated whether MYC-dependent modulation of BMP7 also affected the downstream SMAD signaling pathway. Indeed, the levels of phosphorylated SMAD1/5/8 increased in MYC/BMP7-overexpressing cells, suggesting an enhanced ligand-dependent engagement of the upstream receptors (Figure 4c, left panel) . On the other hand, we observed a significant reduction of SMAD1/5/8 phosphorylation in cells that were depleted of MYC (Figure 4c, right panel) . As further evidence, we report on a BMP7-dependent increase of active SMAD1/5/8 in DAOY V11 and DAOY M2.1 cells, after addition of recombinant BMP7 to the medium (Figure 4f ).
Targeting BMP/SMAD signaling pathway in MB To investigate the relevance of the BMP/SMAD pathway in MB cells, we evaluated the effect of interfering with SMAD activation by using different approaches. Silencing of BMP7 in DAOY M2.1 cells was evaluated in a time-course experiment (Figure 5a ). Along with the decreased amount of secreted BMP7 in the medium (Figure 5b ), BMP7 downregulation induced cell death with concomitant inhibition of cell viability (Figure 5c ). These results indicate the functional relevance of BMP7 as an effector of the prosurvival functions of MYC in MB. On silencing, BMP7 mRNA level decreased by B80%, whereas the secreted BMP7 decreased by B50%, compared with non-targeting-siRNAtransfected cells. This discrepancy could be explained by the documented stability of the BMP7 mRNA (Guhaniyogi and Brewer, 2001; Buijs et al., 2010) , which would justify a higher amount of protein detected than expected. However, we cannot exclude that the cellular responses we observed are associated not only with the downregulation of BMP7 but also with a more general alteration of the entire BMP network following MYC modulation.
The effect of other BMPs and BMPR isoforms was evaluated by silencing BMP2, BMP6 and all known BMPR-I/II receptors, which were found upregulated, together with BMP7, in MYC-overexpressing cells. Among the BMPs, downregulation of BMP6 showed an effect similar to BMP7 silencing (Supplementary Figure  S4A) , whereas among the BMPRs only downregulation of ACVR1 reduced cell viability significantly. Although not considered as direct target of MYC, BMP6 was considered in double-knockout experiments, to prove whether silencing of both BMP6 and BMP7 had a more pronounced effect on cell viability than downregulating BMP7 alone. Single silencing of BMP6 or BMP7 elicited similar effects on cell viability and on induction of apoptosis, as measured at 24-48 h after transfection, whereas silencing of BMP6 alone was more effective after 72 h. Interestingly, the highest level of cell viability inhibition was achieved by the double knockdown (Supplementary Figure S4B) , thus highlighting the relevant role of the BMP pathway for survival of MB cells.
To further study the effect of blocking the BMP/ SMAD signaling pathway in MB cells, we also used dorsomorphin (DM), a small-molecule inhibitor of the BMP-dependent phosphorylation of the SMAD1/5/8 complex (Yu et al., 2008) . MB cells were assessed for cell viability in the presence of increasing concentrations of DM. Interestingly, cells overexpressing MYC were significantly more sensitive to DM than cells bearing one MYC copy (Figure 6a ). In the same cell lines, phosphorylation of SMAD1/5/8 was prevented by DM, confirming the inhibitory effect of the compound on the pathway (Figure 6b ). Furthermore, we found a dose-dependent effect of DM on cell proliferation (Figure 6c ), even though no significant difference in induction of apoptosis was found in cells overexpressing MYC, if compared with wild type and empty-vectortransfected cells (Supplementary Figure S5A) . On the contrary, DM induced a significantly stronger arrest of cell proliferation in cells expressing high MYC (Figure 6c ). This observation suggested that DM can function as a cytotoxic agent inducing block of cell proliferation in a MYC-dependent way.
A panel of four distinct MB-derived cell lines expressing different levels of BMP7 was additionally considered (Supplementary Figure S5B) . The results showed that high BMP7-expressing cells (D425 and MED1) were more sensitive to DM than cells with lower BMP7 levels (D341 and PFSK; Figure 6d ). This observation supported the presence of a BMP7-dependent mechanism sustaining cell survival, which DM is likely to target in MB cells.
Discussion
Owing to the key role in the development of MB, the oncogene MYC and MYC-target genes have become attractive therapeutic targets, in particular to treat the most aggressive MB subtypes (Grotzer et al., 2009) . With the aim of identifying MYC-driven genes or pathways with potentials as therapeutic target, we profiled MB-derived cells by cDNA microarray, following genetic manipulation for either overexpressing or downregulating MYC. The resulting sets of differentially expressed genes were intersected to narrow down the great amount of data generated, and thus to define a group of MYC-responsive genes. These genes included known direct targets, as well as novel candidate target genes of MYC. The gene ontology analysis on the data obtained, allowed identifying pathways that are known already to have a role in onset and progression of MB, but which had not been correlated yet with MYC expression. In particular, we found several components of the BMP/SMAD pathway, known to be physiologically active during embryogenesis, promoting cell proliferation and differentiation of precursor cells of the cerebellum, from which MB arises (Thompson et al., 2006; Gilbertson and Ellison, 2008; Behesti and Marino, 2009; Sutter et al., 2010) . Several in vivo MB models confirmed that an unbalance of proliferative/ differentiation signals, due to aberrant regulation of these pathways, can induce MB tumor formation ( Polkinghorn and Tarbell, 2007) . In our study, BMP7 was found consistently induced/repressed along with the up/downregulation of MYC, respectively, and thus chosen to be investigated in detail Increasing evidences promote the role of the BMP/ SMAD signaling pathway in determining the fate of the GNP cells of the cerebellum. In this context, components of this pathway and in particular BMP7 emerged and were further analyzed for a potential involvement in MYC-driven functions in MB. During the development of the cerebellum, BMP cytokines, including BMP7, are expressed by roof plate cells of the dorsal midline, a region adjacent to the rhombic lip (Alder et al., 1999) , and are known to coordinate proliferation and migration of GNPs (Chizhikov et al., 2006) . Members of the BMP family can in fact induce maturation of GNPs (Alder et al., 1999) and survival of postnatal granule cells (Yabe et al., 2002; Gilbertson and Ellison, 2008) . BMP7 is constitutively expressed by cells of the choroid plexus of the forth ventricle, anatomically closed to the cerebellum (Dziegielewska et al., 2001; Redzic and Segal, 2004) , providing a pro-proliferative sustained signal for the GNP cells (Krizhanovsky and Ben-Arie, 2006; Grimmer and Weiss, 2008) . Thus, determining the correct temporal/spatial organization of cerebellar progenitor cells during early development seems to be the main role of BMP7 (Thompson et al., 2006) . Along with this role, deregulated expression of BMP7 in the cerebellum is very likely associated with abnormal cell development and MB tumorigenesis.
As a validation of our in vitro results, BMP7 was analyzed by immunohistochemistry in primary MB samples. Strikingly, BMP7 was not expressed in normal cerebellum, indicating that overexpression of BMP7 in MB may contribute to the increased proliferation and survival of the tumor cells. Moreover, we found a significant correlation between the gene expression of MYC and BMP7 in two distinct datasets of MB patient samples.
Further, we demonstrated that MYC can bind to the promoter of BMP7 in different MB cell lines by using a ChIP-on-chip approach. That BMP7 is a direct target of MYC was previously reported by Zeller et al. (2006) who performed a global mapping of MYC-binding genomic regions in a model of human B-lymphoid tumor. BMP4, another member of the same family, was described to be a target of MYC in blood cells (Fernandez et al., 2003) . These two reports represent the only experimental evidences, to our knowledge, about a transcriptional control of the BMP pathway by MYC, lacking however of functional information. More specifically, no previous studies have mentioned MYCdriven regulation of this pathway as a significant molecular network in MB.
This investigation, therefore, suggests for the first time the existence of a functional link between the overexpression of MYC and abnormal regulation of the BMP pathway in a model of MB. Furthermore, the functional relevance of the BMP-dependent signaling pathway in MB was evaluated by using DM, a small-molecule inhibitor preventing the activation of SMAD1/5/8 by interfering with the kinase activity of the receptors BMPR-I/II (Anderson and Darshan, 2008; Yu et al., 2008) . Conversely, DM has no, or very limited, effect on other components of the transforming growth factor-b family (fox example, transforming growth factor-b1 and activin A; Anderson and Darshan, 2008) . We reported here the ability of DM to strongly impair proliferation and cell viability of MB-derived cells. More interestingly, cells expressing low MYC levels were significantly less sensitive to DM than cells overexpressing the oncogene, thus indicating that the compound can affect a MYC-driven pro-survival response. Moreover, silencing of BMP7 induced cell death and inhibition of cell viability, although it was not as efficient as DM. This observation, however, is reasonable, because of the ability of the compound to block the pathway by interfering with more components at the same time.
Our results show the feasibility and potential benefit of a selective block of the BMP/SMAD pathway, by either silencing BMP7 or using small-molecule inhibitors. A therapeutic approach interfering with activation of the BMP pathway was investigated here, for the first time, in MB cells and would represent one attractive strategy, to be considered in combination with targeting of sonic hedgehog and Wnt pathways (Chen et al., 2002; Romer and Curran, 2005; Luo et al., 2007; Rossi et al., 2008) . Additional investigations on the role of other BMP family members will emphasize the relevance of the whole pathway in the development of MB. They will also help to shed lights on the emerging recent data showing opposite effects of BMPs, such as BMP2 and BMP4, to whom either anti-apoptotic (Iantosca et al., 1999) or anti-proliferative properties (Zhao et al., 2008) were assigned.
In conclusion, our results provide strong evidence of the induction of BMP7 as a MYC-dependent mechanism and suggest BMP7 as an effector regulatory molecule, in the context of MYC-driven neoplastic transformation of MB precursor cells. This study, not only contributes to a better understanding of the prosurvival functions of MYC in MB, but it also suggests a rationale for targeting the BMP pathway in MB patients with MYC amplification/overexpression.
Materials and methods
MB cell lines
The human MB-derived DAOY, D341, D425, MED-1 and PFSK cell lines used in this study were obtained and maintained in culture as previously described (von Bueren et al., 2007) . The stable clones DAOY V11 (empty vector transfected), DAOY M2.1 and DAOY M14 (MYC vector transfected) were maintained in selective medium in the presence of 500 mg/ml G418 (Stearns et al., 2006) .
RNA interference
The cells (70-80% confluent) were transfected using either SMARTpool siRNA specific for MYC or siCONTROL Non-targeting siRNA Pool as a control (Dharmacon, Thermo Fisher Scientific, Waltham, MA, USA). Each pool of siRNA was used at the final concentration of 50 nM in combination with Dharmafect 4 transfection reagent (Dharmacon), according to the manufacturer's instructions. Cells were harvested for both mRNA and protein extraction, to assess gene expression by quantitative real-time PCR and protein content by immunoblotting. To selectively target BMP7 and other components of the BMP/SMAD pathway (BMP2, BMP6 and BMP receptors BMPR1A, BMPR1B, BMPR2, ACVR1, ACVR1B, ACVR1C, ACVR2A, ACVR2B and ACVRL1), Ambion Silencer select predesigned siRNAs (Ambion Diagnostics, Applied Biosystems, Foster City, CA, USA) were used at 20 nM final concentration. As control, Silencer Negative Control siRNA #1 (cat. AM4611; Ambion Diagnostics) was used under the same conditions.
DNA microarray expression profiling and data analysis
The cDNA microarray analysis was performed in collaboration with the Functional Genomic Center of the University Zurich. Gene expression data were obtained by hybridizing Human Genome-U133 Plus 2.0 Affymetrix GeneChips arrays (Affymetrix, Santa Clara, CA, USA), on which >47 000 transcripts were represented. Raw data generated by the GCOS Software (Affymetrix) were processed by using the RMA method (Irizarry et al., 2003) and further statistically analyzed by using the software R and applying Student's t-test. Each experiment represented a group of three independent biological replicates. A gene was considered expressed only if the average normalized signal in at least one of the two groups compared was above 25. Results are expressed as fold change, and differences in expression were considered significant if fold change X2.0 and P-value o0.01. The expression data were deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO series accession number GSE22139 (http://www.ncbi.nlm.nih.gov/geo). Cluster analysis of the data was performed by using the heatmap.2 method of the 'gplots' package (R Development Core Team, 2008) . The GeneGO MetaCore (GeneGO, St Joseph, MI, USA) was used to define functional annotations for the selected genes, thus assigning them to ontological categories for association with relevant biological processes and pathways.
MB TMA and BMP7/MYC correlation study in MB patient samples The tumor material used to create the MB TMA originates from three sets of archival MB samples, diagnosed in Zurich, Switzerland (n ¼ 46), Cairo, Egypt (n ¼ 14) and Tu¨bingen, Germany (n ¼ 6). All these tumor samples were reviewed independently by two neuropathologists and diagnosed as MB.
TMA paraffin sections were deparaffinized in xylene and rehydrated stepwise with ethanol. The immunohistochemistry determination of BMP7 was carried out using the catalyzed signal amplification II system (Dako, Glostrup, Denmark) according to the manufacturer's protocol. The endogenous peroxidase activity was blocked incubating the specimens with 0.3% H 2 O 2 for 5 min, followed by 5 min with a protein-based blocking reagent and incubation with a BMP7-specific antibody (Abcam, Cambridge, UK; 1:3000), for 30 min at room temperature. The signal was detected in the presence of diaminobenzidine. Immunoreactivity was scored as (i) À, if o10%; (ii) þ , if 10-50%; (iii) þ þ , if 51-90%; (iv) þ þ þ , if 490% of neoplastic cells with cytoplasmic staining for BMP7. Human normal kidney tissues on paraffin sections served as a positive control. From a subset of 38 samples from the MB patients diagnosed in Zurich (Switzerland) sufficient tumor material was available to perform quantitative real-time PCR for the analysis of BMP7 and MYC mRNA expression. Total RNA was isolated from formalin-fixed paraffin-embedded tumor tissue as described previously (Kunz et al., 2006) by using the Optimum formalin-fixed paraffin-embedded for paraffin block RNA isolation kit (Ambion Diagnostics). Paraffin from 1 Â 20 to 2 Â 20 mm slices of formalin-fixed paraffin-embedded MB samples was removed by washing the samples with xylene for 30 min. Samples were collected by centrifugation, washed with ethanol,and allowed to air dry at room temperature prior final centrifugation. Samples were then resuspended in 10 ml (60 U/ml) proteinase K and 100 ml of digestion buffer, and incubated at 371C for 3 h and then at room temperature for further 12 h. After complete digestion, RNA was extracted according to the manufacturer's protocol.
To validate our results, expression data obtained from a different group of primary MB tumors (Thompson et al., 2006) was used to perform an unsupervised analysis on the mRNA expression of BMP7 and MYC.
Cell viability, cell proliferation and apoptosis assays Cell viability was evaluated using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (Promega Corporation, Madison, WI, USA) based on the reactivity of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). Alternatively, the number of viable cells was determined by trypan blue exclusion using a hemocytometer. Proliferation was quantified by the chemiluminescence-based Cell Proliferation ELISA BrdU (F HoffmannLa Roche AG, Basel Switzerland). Activation of caspases 3 and 7 was detected by using the Caspase-Glo 3/7 Assay (Promega Corporation); hystone-associated DNA fragments were quantified by Cell Death Detection ELISA PLUS assay (Roche Diagnostics). Data are expressed as average values from three independent experiments.
Gene expression analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Basel, Switzerland) following the manufacturer's instructions. After enzymatic digestion of DNA with RNase-free DNase (Qiagen), 0.5-1 mg of total RNA was used as template for reverse transcription, which was triggered by random hexamer primers and performed by using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR was performed under conditions optimized for the ABI7900HT instrument, using Gene Expression Master Mix (Applied Biosystems). Probe-primer specific for the following genes (purchased from Applied Biosystems) were used: MYC (Hs00153408_m1), BMP7 (Hs00233476_m1), TERT (Hs00162669_m1), CCND2 (Hs00277041_m1) and CCNA2 (Hs00153138_m1). Normal human cerebellum was used as a reference (Clontech-Takara Bio Europe, SaintGermain-en-Laye, France). The relative gene expression was calculated for each gene of interest by using the DDC T method, where cycle threshold (C T ) values were normalized to the housekeeping genes succinate dehydrogenase complex subunit A (SDHA) (Hs00188166_m1) and b-actin (Hs99999903_m1).
Western blot analysis and ELISA Total protein extracts were obtained from 0.5-1.5 Â 10 6 cells lysed with RIPA buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche Applied Sciences) and with the phosphatase inhibitors b-glycerophosphate (20 mM) and Na 3 VO 4 (200 mM). Proteins were resolved by SDS-polyacrylamide gel electrophoresis and western blotting on polyvinylidene fluoride membranes (Amersham, GE Healthcare, UK). After binding of the indicated antibodies, the signal was detected by chemiluminescence using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific Inc., Rockford, IL, USA). Antibodies specific for BMP7 (4E7) and SMAD 1/5/8 (N-18) were purchased from Santa Cruz Biotechnology Inc., whereas antibodies against phospho-SMAD1 (Ser463/465), SMAD5 (Ser463/465), SMAD8 (Ser426/428) and MYC were from Cell Signaling Technology, Inc. (Danvers, MA, USA). As loading controls, b-tubulin and b-actin (Sigma-Aldrich Chemie GmbH, Buchs, Germany) were detected. According to the experimental setting, cells were incubated in the presence of human recombinant BMP7 (Calbiochem-Merck, Darmstadt, Germany) for 0.5 or 1 h, and cell lysates were analyzed by western blotting. To quantify secreted BMP7 in cell supernatants (100 ml from each sample), the human BMP7 ELISA kit (RayBiotech Inc., Norcross, GA, USA) was used following the manufacturers' instructions.
ChIP-on-chip
ChIP-on-chip experiments using a MYC antibody were performed as previously described (Ma et al., 2010) . The MB-derived cell lines D487 and D283 were used in this study.
Statistical analysis
All experiments were performed at least in triplicates. Data are represented as mean ± s.d. For in vitro experiments, the Student's t-test was used. P-values of o0.01 were considered significant. Pearson's correlation test and Fisher's exact test were used for in vivo gene correlation.
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